Literature DB >> 6194116

Common lipopolysaccharide specificity: new type of antigen residing in the inner core region of S- and R-form lipopolysaccharides from different families of gram-negative bacteria.

H Brade, C Galanos.   

Abstract

A new antigenic specificity, referred to here as common lipopolysaccharide (LPS) specificity, is described in the LPSs of gram-negative bacteria belonging to various families. The specificity is present in S- and R-form LPS but absent in Re mutants of different enterobacterial genera. By the use of purified LPS and monospecific antibodies obtained by immunoabsorption, the specificity is differentiated from the known core specificities of the genus Salmonella and the lipid A specificity by aid of the passive hemolysis and passive hemolysis inhibition test. In Salmonella minnesota R-form LPS, the specificity may be cryptic (R345, Rb2 mutant) or partly exposed in the intact molecule (R7, Rd1 mutant). The specificity is either demasked or completely exposed after mild acid hydrolysis for a short time, whereas it is destroyed after prolonged hydrolysis. Periodate oxidation, reduction, and hydrolysis under conditions that do not affect the ketosidic linkages of 2-keto-3-deoxyoctulosonic acid destroy the specificity in R4 (Rd2 mutant) LPS, but do not do so in R7 LPS. It is suggested that 2-keto-3-deoxyoctulosonic acid and a following neutral sugar are the compositional requirements for expressing the specificity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6194116      PMCID: PMC264551          DOI: 10.1128/iai.42.1.250-256.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Treatment of E. coli and klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-gal epimerase-deficient mutant.

Authors:  E J Ziegler; H Douglas; J E Sherman; C E Davis; A I Braude
Journal:  J Immunol       Date:  1973-08       Impact factor: 5.422

2.  Protection against gram-negative infections with antiserum to lipid A from Salmonella minnesota R595.

Authors:  N A Mullan; P M Newsome; P G Cunnington; G H Palmer; M E Wilson
Journal:  Infect Immun       Date:  1974-12       Impact factor: 3.441

3.  Structural investigations on the 2-keto-3-deoxyoctonate region of lipopolysaccharides.

Authors:  W Dröge; V Lehmann; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1970-05-01

4.  A new method for the extraction of R lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1969-06

5.  Structural relationship of Salmonella O and R antigens.

Authors:  O Lüderitz; C Galanos; H J Risse; E Ruschmann; S Schlecht; G Schmidt; H Schulte-Holthausen; R Wheat; O Westphal; J Schlosshardt
Journal:  Ann N Y Acad Sci       Date:  1966-06-30       Impact factor: 5.691

6.  Functional role of antibody against "core" glycolipid of Enterobacteriaceae.

Authors:  L S Young; P Stevens; J Ingram
Journal:  J Clin Invest       Date:  1975-10       Impact factor: 14.808

7.  Cell-wall lipopolysaccharide from Escherichia coli B.

Authors:  P Prehm; S Stirm; B Jann; K Jann
Journal:  Eur J Biochem       Date:  1975-08-01

8.  Electrodialysis of lipopolysaccharides and their conversion to uniform salt forms.

Authors:  C Galanos; O Lüderitz
Journal:  Eur J Biochem       Date:  1975-06

9.  Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides.

Authors:  C Galanos; O Lüderitz; O Westphal
Journal:  Eur J Biochem       Date:  1971-12-22

10.  Isolation and analysis of the lipid A backbone. Lipid A structure of lipopolysaccharides from various bacterial groups.

Authors:  S Hase; E T Rietschel
Journal:  Eur J Biochem       Date:  1976-03-16
View more
  15 in total

1.  [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].

Authors:  E T Rietschel; H Brade
Journal:  Infection       Date:  1987 Mar-Apr       Impact factor: 3.553

2.  [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].

Authors:  E T Rietschel; H Brade
Journal:  Infection       Date:  1987       Impact factor: 3.553

Review 3.  Lipopolysaccharide nomenclature--past, present, and future.

Authors:  P J Hitchcock; L Leive; P H Mäkelä; E T Rietschel; W Strittmatter; D C Morrison
Journal:  J Bacteriol       Date:  1986-06       Impact factor: 3.490

4.  Characterization of anti-core glycolipid monoclonal antibodies with chemically defined lipopolysaccharides.

Authors:  J de Jongh-Leuvenink; J Schellekens; J Verhoef
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

5.  Antigenic properties of Chlamydia trachomatis lipopolysaccharide.

Authors:  L Brade; M Nurminen; P H Mäkelä; H Brade
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

6.  Bactericidal and opsonizing effects of normal serum on mutant strains of Salmonella typhimurium.

Authors:  M F Shaio; H Rowland
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

7.  The tetrasaccharide L-alpha-D-heptose1-->2-L-alpha-D-heptose1--> 3-L-alpha-D-heptose1-->(3-deoxy-D-manno-octulosonic acid) and phosphate in lipid A define the conserved epitope in Haemophilus lipopolysaccharides recognized by a monoclonal antibody.

Authors:  S Borrelli; O Hegedus; D H Shaw; P E Jansson; A A Lindberg
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  A 28,000-dalton protein of normal mouse serum binds specifically to the inner core region of bacterial lipopolysaccharide.

Authors:  L Brade; H Brade
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

9.  Cross-reactivity of monoclonal antibodies and sera directed against lipid A and lipopolysaccharides.

Authors:  H M Kuhn
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

10.  Campylobacter jejuni outer membrane proteins are antigenic for humans.

Authors:  M J Blaser; J A Hopkins; M L Vasil
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.